COM:PHASEBIO
PhaseBio Pharmaceuticals, Inc.
- Stock
Last Close
0.07
17/09 20:00
Volume Today
8.56M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | ||
|---|---|---|---|---|---|---|---|
average inventory | |||||||
average payables | 431.50K - | 1.12M 159.10% | 2.36M 111.40% | 3.30M 39.52% | 8.12M 146.31% | ||
average receivables | 116.50K - | 733K 529.18% | 616.50K 15.89% | ||||
book value per share | -7.04 - | -8.66 23.07% | 9.60 210.87% | 2.18 77.28% | -0.87 139.76% | -3.16 264.87% | |
capex per share | -0.01 - | -0.02 153.09% | -0.02 16.84% | -0.03 55.66% | -0.05 39.17% | -0.09 87.53% | |
capex to depreciation | -1.02 - | -2.25 120.21% | -1.13 49.63% | -5.52 386.82% | -2.78 49.62% | -1.49 46.24% | |
capex to operating cash flow | 0.01 - | 0.03 169.55% | 0.01 73.32% | 0.02 247.45% | 0.02 2.87% | 0.06 139.91% | |
capex to revenue | -0.18 - | -0.41 128.25% | -4.41 985.20% | -247.35 5,505.57% | |||
cash per share | 0.30 - | 1.19 297.46% | 11.50 865.52% | 2.69 76.60% | 0.97 64.05% | 1.42 46.91% | |
days of inventory on hand | |||||||
days payables outstanding | |||||||
days sales outstanding | 127.31 - | 190.62 49.72% | |||||
debt to assets | 22.18 - | 7.91 64.33% | 0.19 97.57% | 0.27 42.18% | 1.50 449.74% | 2.54 69.06% | |
debt to equity | -1.05 - | -1.14 9.31% | 0.24 120.75% | 0.38 58.01% | -3.00 898.64% | -1.65 44.94% | |
dividend yield | |||||||
earnings yield | -0.15 - | -0.18 22.41% | -1.45 698.62% | -0.23 83.94% | -1.01 332.12% | -0.00 99.83% | |
enterprise value | 58.25M - | 58.33M 0.15% | -37.14M 163.67% | 108.66M 392.59% | 81.64M 24.87% | 42.77M 47.60% | |
enterprise value over ebitda | -6.38 - | -7.85 23.07% | 1.87 123.86% | -2.86 252.60% | -0.84 70.45% | 25.73 3,144.67% | |
ev to operating cash flow | -6.01 - | -7.06 17.47% | 2.18 130.84% | -2.74 226.02% | -1.36 50.39% | -0.90 33.75% | |
ev to sales | -55.60 - | 46.02 182.78% | 255.11 454.29% | 3.95K 1,448.01% | |||
free cash flow per share | -0.79 - | -0.75 4.57% | -3.24 329.72% | -1.48 54.43% | -2.11 43.19% | -1.70 19.32% | |
free cash flow yield | -0.16 - | -0.15 4.57% | -1.05 595.35% | -0.24 76.95% | -0.63 160.38% | -0.65 3.87% | |
graham net net | -7.07 - | -8.72 23.38% | 9.26 206.16% | 1.91 79.40% | -1.63 185.60% | -3.80 132.89% | |
graham number | 10.85 - | 13.32 22.74% | 31.16 133.93% | 8.37 73.14% | 8.14 2.80% | 0.56 93.07% | |
income quality | 1.05 - | 0.81 23.29% | 0.72 11.27% | 1.01 41.07% | 0.61 39.70% | 361.76 59,370.44% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -3.14 - | -5.01 59.66% | -36.93 637.68% | -58.72 59.02% | 113.37K 193,157.16% | ||
interest debt per share | 0.48 - | 2.15 353.04% | 0.57 73.35% | 0.47 18.61% | 0.27 42.88% | ||
inventory turnover | |||||||
invested capital | -0.03 - | 0.15 646.53% | 0.25 66.47% | -0.48 296.30% | -0.08 82.48% | ||
market cap | 61.96M - | 56.26M 9.21% | 16.39M 70.86% | 167.99M 924.76% | 97.63M 41.88% | 76.73M 21.41% | |
net current asset value | -87.42M - | -97.77M 11.84% | 50.53M 151.68% | 56.31M 11.44% | -35.41M 162.89% | -104.79M 195.93% | |
net debt to ebitda | 0.41 - | -0.28 168.64% | 2.70 1,066.99% | 1.56 42.20% | 0.17 89.40% | -20.42 12,436.58% | |
net income per share | -0.74 - | -0.91 22.41% | -4.49 393.55% | -1.43 68.24% | -3.39 137.63% | -0.00 99.87% | |
operating cash flow per share | -0.78 - | -0.73 6.10% | -3.21 337.91% | -1.44 55.20% | -2.06 43.29% | -1.61 21.84% | |
payables turnover | |||||||
receivables turnover | 2.87 - | 1.91 33.21% | |||||
research and ddevelopement to revenue | 23.14 - | 13.09 43.41% | 225.28 1,620.66% | 9.43 95.82% | |||
return on tangible assets | -2.24 - | -0.73 67.55% | -0.38 47.94% | -0.48 25.74% | -1.96 311.41% | -0.00 99.89% | |
revenue per share | 0.13 - | 0.09 31.80% | 0.01 87.18% | 0.00 96.65% | |||
roe | 0.11 - | 0.11 0.54% | -0.47 545.14% | -0.65 39.75% | 3.91 697.69% | 0.00 99.96% | |
roic | 2.54 - | 0.65 74.39% | 0.32 50.30% | 0.58 79.73% | 8.88 1,429.47% | 3.05 65.63% | |
sales general and administrative to revenue | 7.27 - | 4.74 34.84% | 40.90 763.27% | 1.49 96.37% | |||
shareholders equity per share | -7.04 - | -8.66 23.07% | 9.60 210.87% | 2.18 77.28% | -0.87 139.76% | -3.16 264.87% | |
stock based compensation to revenue | 0.50 - | 0.60 21.10% | 6.99 1,061.50% | 209.40 2,895.43% | |||
tangible asset value | -87.18M - | -97.42M 11.74% | 50.93M 152.28% | 59.98M 17.77% | -25.20M 142.02% | -93.03M 269.15% | |
tangible book value per share | -7.04 - | -8.66 23.07% | 9.60 210.87% | 2.18 77.28% | -0.87 139.76% | -3.16 264.87% | |
working capital | 3.04M - | -3.85M 226.61% | 58.05M 1,608.21% | 70.34M 21.18% | 25.19M 64.19% | 20.90M 17.02% |
All numbers in USD (except ratios and percentages)